Výsledky vyhledávání

Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?

Autor: S C, Wong, T, Sanborn, L A, Sleeper, J G, Webb, R, Pilchik, D, Hart, S, Mejnartowicz, T A, Antonelli, R, Lange, J K, French, G, Bergman, T, LeJemtel, J S, Hochman

Publikováno v: Journal of the American College of Cardiology. 36(3 Suppl)

We sought to delineate the angiographic findings, clinical correlates and in-hospital outcomes in patients with cardiogenic shock (CS) complicating acute myocardial infarction.Patients with CS complicating acute myocardial infarction carry a grave pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c2ab541e4766998fb3a33328caff2488
https://pubmed.ncbi.nlm.nih.gov/10985708

Zobrazit plný text záznamu

Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?

Autor: J S, Hochman, C E, Buller, L A, Sleeper, J, Boland, V, Dzavik, T A, Sanborn, E, Godfrey, H D, White, J, Lim, T, LeJemtel

Publikováno v: Journal of the American College of Cardiology. 36(3 Suppl)

This SHOCK Study report seeks to provide an overview of patients with cardiogenic shock (CS) complicating acute myocardial infarction (MI) and the outcome with various treatments. The outcome of patients undergoing revascularization in the SHOCK Tria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::08add65c95dc100869cbcaf6546228e2
https://pubmed.ncbi.nlm.nih.gov/10985706

Zobrazit plný text záznamu

Cardiogenic shock with non-ST-segment elevation myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded coronaries for Cardiogenic shocK?

Autor: A K, Jacobs, J K, French, J, Col, L A, Sleeper, J N, Slater, L, Carnendran, J, Boland, X, Jiang, T, LeJemtel, J S, Hochman

Publikováno v: Journal of the American College of Cardiology. 36(3 Suppl)

We sought to determine the outcomes of patients with cardiogenic shock (CS) complicating non-ST-segment elevation acute myocardial infarction (MI).Such patients represent a high-risk (ST-segment depression) or low-risk (normal or nonspecific electroc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::09db3ab72ddcb9bd48a281f2efa55fab
https://pubmed.ncbi.nlm.nih.gov/10985710

Zobrazit plný text záznamu

The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK?

Autor: V, Menon, H, White, T, LeJemtel, J G, Webb, L A, Sleeper, J S, Hochman

Publikováno v: Journal of the American College of Cardiology. 36(3 Suppl)

We sought to evaluate the frequency of pulmonary congestion and associated clinical and hemodynamic findings in patients with suspected cardiogenic shock (CS).The prevalence of pulmonary congestion in the setting of CS is uncertain.The 571 SHOCK Tria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4e1fa31fbcebde9a36ddb2edd11c7cc5
https://pubmed.ncbi.nlm.nih.gov/10985707

Zobrazit plný text záznamu

SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK: an international randomized trial of emergency PTCA/CABG-trial design. The SHOCK Trial Study Group

Autor: J S, Hochman, L A, Sleeper, E, Godfrey, S M, McKinlay, T, Sanborn, J, Col, T, LeJemtel

Publikováno v: American heart journal. 137(2)

Cardiogenic shock (CS) is the leading cause of death in patients hospitalized with acute myocardial infarction (MI). Nonrandomized studies suggest reduced mortality rate with revascularization.The SHOCK trial is a multicenter, randomized, and unblind

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::aa8f79ff4e36e07ce58cd05292848409
https://pubmed.ncbi.nlm.nih.gov/9924166

Zobrazit plný text záznamu

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group

Autor: J N, Cohn, M B, Fowler, M R, Bristow, W S, Colucci, E M, Gilbert, V, Kinhal, S K, Krueger, T, Lejemtel, K A, Narahara, M, Packer, S T, Young, T L, Holcslaw, M A, Lukas

Publikováno v: Journal of cardiac failure. 3(3)

Many patients remain markedly symptomatic despite optimal current therapy for heart failure. Beta-blockers have often been viewed as contraindicated in this group because of their potential adverse short-term effects on cardiac function.One hundred t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0415c5242e4d049dd0bea74b9ede3bb3
https://pubmed.ncbi.nlm.nih.gov/9330125

Zobrazit plný text záznamu

Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure

Autor: K, Dickstein, S, Gottlieb, E, Fleck, J, Kostis, B, Levine, M, DeKock, T, LeJemtel

Publikováno v: Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 12(2)

Losartan is a specific angiotensin II receptor antagonist with no agonist properties. This agent permits evaluation of the response to selective angiotensin II antagonism in patients with congestive heart failure.A study was designed to assess the ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b5aaf937549826b227bb6c481e916246
https://pubmed.ncbi.nlm.nih.gov/7965263

Zobrazit plný text záznamu

Cardiogenic Shock: How should we Revascularize?

Autor: J. Hochman, J. Col, T. Lejemtel

Publikováno v: Yearbook of Intensive Care and Emergency Medicine 1994 ISBN: 9783540576136

Cardiogenic shock remains the leading cause of death in patients hospitalized with acute myocardial infarction (AMI). The incidence (7.5%) and mortality (80%) were unchanged from 1975 to 1988 in a report of the Worcester, Massachusetts Community [1].

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ee18624f648b52f61448f9da32169bf
https://doi.org/10.1007/978-3-642-85068-4_28

Zobrazit plný text záznamu

Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators

Autor: W S, Colucci, E H, Sonnenblick, K F, Adams, M, Berk, S C, Brozena, A J, Cowley, J M, Grabicki, S A, Kubo, T, LeJemtel, W A, Littler

Publikováno v: Journal of the American College of Cardiology. 22(4 Suppl)

We describe the results of two placebo-controlled trials (MIL-1077 and MIL-1078) designed to evaluate the clinical efficacy of oral milrinone administered together with converting enzyme inhibitors to patients with congestive heart failure. Although

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ca9a9d1d8c64dd016dc9cfb480abc244
https://pubmed.ncbi.nlm.nih.gov/8376682

Zobrazit plný text záznamu

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

Autor: E Fleck, J Kostis, K Dickstein, M DeKock, Stephen S. Gottlieb, T LeJemtel, T B Levine

Publikováno v: Circulation. 88(4 Pt 1)

BACKGROUND Losartan is a new specific angiotensin II receptor antagonist with no agonist properties that provides the opportunity to study the consequences of angiotensin II blockade. The objective of the present study was to evaluate the hemodynamic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c92f94564bce99c64f8477f80057456
https://pubmed.ncbi.nlm.nih.gov/8403307

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání